MabCure, Inc. (MBCI)
$0.0003
-0.01 (-96.67%)
Rating:
Recommendation:
-
| Symbol | MBCI |
|---|---|
| Price | $0.0003 |
| Beta | 13.971 |
| Volume Avg. | 0.00M |
| Market Cap | 0.644M |
| Shares () | - |
| 52 Week Range | 2.0E-4-0.009 |
| 1y Target Est | - |
| DCF Unlevered | MBCI DCF -> | |
|---|---|---|
| DCF Levered | MBCI LDCF -> | |
| ROE | -127.05% | Strong Sell |
| ROA | -258.80% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 6.74% | Neutral |
| P/E | -0.03 | Neutral |
| P/B | - |
About
Download (Excel)MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.